USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
abervitinib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment
avapasem manganese: treatment of mucositis
avelintinib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment
orliteganib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment
risuteganib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment
samitolisib: treatment of cancer
saritolisib: treatment of cancer
suritolisib: treatment of cancer
burtomab: treatment of pediatric cancers
lisocabtagene maralentileucel: antineoplastic, autologous genetically modified cellular therapy
reluperidone: treatment of schizophrenia
solorinab: treatment of pain
aprolesel: treatment of hematologic malignancies
anabasum: treatment of cystic fibrosis
bomanezumab pegol: treatment of Alzheimer’s Disease
clatimagene carmaleucel: treatment of potential transplant rejection
contesolid acefosamil: antibiotic
covolizumab: treatment of cancer, checkpoint inhibitor
donislecel: cellular therapy treatment for diabetes
dovocizumab: treatment of hypercholesterolemia
ermekumab: cachexia, oncology, vascular disease, diabetes, psoriasis, acne, etc.
esimipasem manganese: treatment of mucositis
fidanacogene elaparvovec: treatment of hemophilia B
filoteganib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment
hydromorphisal: treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase gene
iblamterene: treatment of cystic fibrosis and primary ciliary dyskinesia
marstacumab: preventing bleeding episodes in adults and children with hemophilia
nirsevumab: treatment of respiratory syncytial virus
odatilumab: treatment of osteoarthritis and rheumatoid arthritis
ostarlizumab: treatment of cancer, checkpoint inhibitor
sedotristat: treatment of pulmonary arterial hypertension
sontimesel: treatment of hematologic malignancies
subitolisib: treatment of cancer
tofersen: treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase gene
trigriluzole: treatment of spinocerebellar ataxia